SELL and lobular neoplasia: In the current study, we aim to systematically validate L-selectin as a urinary biomarker of disease activity and treatment response in LN patients across multiple ethnicities, cohorts and test centers, a pre-requisite for eventually using these biomarkers in clinical practice.